Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.76 |
| ▸ | NPC1 | O15118 | 5/20 | 0.76 |
| ▸ | RAB9A | P51151 | 5/20 | 0.76 |
| ▸ | HPGD | P15428 | 5/20 | 0.76 |
| ▸ | MAOA | P21397 | 5/20 | 0.76 |
| ▸ | MAOB | P27338 | 5/20 | 0.76 |
| ▸ | MAPT | P10636 | 4/20 | 0.76 |
| ▸ | ALDH2 | P05091 | 4/20 | 0.76 |
| ▸ | TP53 | P04637 | 3/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.76 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.76 |
| ▸ | CA12 | O43570 | 1/20 | 0.76 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12238027 | 0.90 | KDM4E (0.72) | KDM4EALDH1A1HSD17B10SMN1; SMN2NPC1 | |
| SCHEMBL809995 | 0.89 | NPC1 (0.57) | KDM4EALDH1A1HSD17B10SMN1; SMN2NPC1 | |
| Daidzein SCHEMBL21114371 | 0.87 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10SMN1; SMN2NPC1 | |
| Daidzein SCHEMBL29374778 | 0.87 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10SMN1; SMN2NPC1 | |
| Daidzein SCHEMBL19814 | 0.87 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10SMN1; SMN2NPC1 | |
| SCHEMBL12289032 | 0.86 | KDM4E (0.76) | KDM4EALDH1A1HSD17B10SMN1; SMN2NPC1 | |
| SCHEMBL2349506 | 0.85 | KDM4E (0.83) | KDM4EALDH1A1HSD17B10SMN1; SMN2NPC1 | |
| Daidzein SCHEMBL19410270 | 0.83 | KDM4E (0.86) | KDM4EALDH1A1HSD17B10SMN1; SMN2NPC1 | |
| SCHEMBL4683689 | 0.82 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10SMN1; SMN2NPC1 | |
| SCHEMBL2549643 | 0.82 | KDM4E (0.83) | KDM4EALDH1A1HSD17B10SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3021843-A2 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2016-05-25 | — | — | EP | disclosed |
| WO-2016073947-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2016-05-12 | — | — | WO | disclosed |
| WO-2016073947-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2016-05-12 | — | — | WO | disclosed |
| US-20160122312-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | Kineta, Inc. | 2016-05-05 | — | — | US | disclosed |
| US-20160122312-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | Kineta, Inc. | 2016-05-05 | — | — | US | disclosed |
| US-20160122312-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | Kineta, Inc. | 2016-05-05 | — | — | US | disclosed |
| WO-2015009812-A2 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2015-01-22 | — | — | WO | disclosed |
| WO-2015009812-A2 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122312-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | MAVS, EIF2AK2, IRF3 | KDM4E 2241/4885ALDH1A1 3052/4885HSD17B10 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.